Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.

Karen E Elkind-HirschN ChappellEricka SeidemannJohn StormentDrake Bellanger

Published in: The Journal of clinical endocrinology and metabolism (2021)

Dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.

Keyphrases

polycystic ovary syndrome
insulin resistance

case report
type diabetes

mesenchymal stem cells
bone marrow

smoking cessation
replacement therapy